No Data
GNI Group Issues Stock Options Tied to Drug Approval Milestone
GNI Group Expects Record 2025 Sales Despite Tariff Concerns
GNI Group: Financial Report - 24th Term (2024/01/01 - 2024/12/31)
GNI Group: Confirmation
GNI Group: Extraordinary Report
Announcement of the release of the thrombocytopenia (TP) treatment drug "Kangquxin" developed by Peking Continent Company.
GNIV Group, Inc. (hereinafter referred to as "the Company" including subsidiaries and affiliated companies as "the Company Group") announced that its main subsidiary, Peking Continental Pharmaceutical Co., Ltd. (hereinafter referred to as "Peking Continental"), has started sales of the drug Abatrombopag Mesylate Tablets "Kōkukushin" (English name: CONTIVA) after obtaining manufacturing and sales approval. Please refer to the press release of Peking Continental at the link below. 新闻动
